The true test of whether small-cap biotech stocks can sustain this rally will come after the near-term catalysts like FDA decisions and medical meetings pass and the companies inevitably raise cash by selling stock.So far, however, investors are loving the risky biotech stuff and eschewing their larger, more successful cousins. As of last week, micro-cap biotech stocks were up almost 60% this year, while large-cap biotech stocks were down 38%.
Tiny Biotechs Dancing in the Bull Pen
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts